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Variability of human pluripotent stem cell lines 
 
Abstract:  
Human pluripotent stem cells derived from embryos (human Embryonic Stem Cells or 
hESCs) or generated by direct reprogramming of somatic cells (human Induced Pluripotent 
Stem Cells or hiPSCs) can proliferate almost indefinitely in vitro while maintaining the capacity 
to differentiate into a broad diversity of cell types. These two properties (self-renewal and 
pluripotency) confers human pluripotent stem cells a unique interest for clinical applications 
since they could allow the production of infinite quantities of cells for disease modelling, drug 
screening and cell based therapy. However, recent studies have clearly established that 
human pluripotent stem cells lines can display variable capacity to differentiate into specific 
lineages. Consequently, the development of universal protocols of differentiation which could 
work efficiently with any human pluripotent cell line is complicated substantially. As a 
consequence, each protocol needs to be adapted to every cell line thereby limiting large scale 
applications and precluding personalised therapies. Here, we summarise our knowledge 
concerning the origin of this variability and describe potential solutions currently available to 
bypass this major challenge. 
 
Introduction 
The derivation of human embryonic stem cells (hESCs) [1] opened exciting 
opportunities for translational research and regenerative medicine. Almost a decade later, 
direct reprogramming of human somatic cells to pluripotency [2] promised to overcome ethical 
limitations associated with human embryos and enable personalised therapies. However, the 
clinical applications of hESCs and hiPSCs continue to be limited by their inherent variability in 
differentiation capacity [3–5]. Indeed, protocols of differentiation appear to work efficiently only 
with specific cell lines thereby precluding the use of a broad spectrum of human pluripotent 
stem cells (hPSCs). This challenge is exacerbated by the lack of a precise test to evaluate the 
level of reprogramming in hiPSCs. In contrast to mouse ESCs, hPSCs pluripotency cannot be 
assessed through chimera formation or tetraploid complementation assays. As a 
consequence, reprogramming of human cells can only be confirmed through relatively crude 
characterisations such as gene expression profiling, in vitro differentiations or teratoma 
formation none of which is sufficient to determine the capacity of differentiation of individual 
hiPSCs into a specific cell types. Thus, the origins of this functional variability remain an active 
field of investigation within the stem cell community. Some of the previous findings and more 
recent developments will be discussed here. 
 
Gene expression and signalling variability 
There has been a diversity of attempts to find markers characterising hPSC variability 
and predicting their capacity of differentiation. Indeed, differences in gene expression 
controlling endogenous signalling are likely to alter cellular behaviour and differentiation 
potential in vitro. This variability in signalling pathway activity may be counteracted by line 
specific optimisation of differentiation protocols, adapting the concentration of cytokines and 
inhibitors according to the cell line used [6]. Accordingly, several reports have shown that 
varying gene expression profiles in hPSCs could be associated with divergent capacities of 
differentiation. Blauwkamp and colleagues correlated the expression of early lineage markers 
in undifferentiated hPSCs [7] with the level of endogenous Wnt signalling resulting in distinct 
differentiation propensities. Elevated Wnt would thereby lead to enhanced differentiation 
potential towards mesendoderm, which was confirmed by a separate report [8]. However, wnt-
high and wnt-low subpopulations in normal culture seem to change dynamically rather than 
represent a stable state.  
The expression of micro-RNAs was shown to serve as an indicator of neural 
differentiation propensity [9]. In a recent study, Nishizawa and colleagues compared 35 
different hiPSC lines of different origin and four hESC lines in their ability to form hematopoietic 
cells [10]. This analysis revealed that the differentiation potential of hPSC lines could correlate 
with the expression of IGF2. This gene is not directly implicated in the hematopoietic 
differentiation, but seems to serve as an indicator of chromatin accessibility at loci of 
mesendodermal genes which could render them more amenable for activation. Interestingly, 
the maturation capacity of different lines was less correlated with varying gene expression 
patterns, but instead seemed to be influenced by changes in DNA methylation [10] suggesting 
that epigenetic rather than genetic regulations could be involved. Importantly, this study seems 
to contradict a previous report showing that the endogenous level of Nodal growth factor in 
hESCs could predict their capacity to differentiate into blood progenitors [11]. This underlines 
the difficulty of such experimental comparisons requiring a larger number of independent 
experimental samples that can be easily influenced by culture conditions, handling skills, 
methods of analysis and the quality of the hPSC lines used. 
 
DNA methylation and epigenetic memory 
Variations in the transcriptome could originate from a diversity of mechanisms. One 
source could be epigenetic differences induced by either abnormal/incomplete reprogramming 
[12] or by culture conditions [13–16]. In particular, hiPSCs have been under intense scrutiny 
as to their similarity with hESCs. Indeed, a methylation analysis of preselected CpG sites 
concluded that there is a core set of aberrantly methylated genes that can distinguish hiPSCs 
from hESCs regardless of the donor cell type [17]. This “reprogramming-associated epigenetic 
signature” was characterised mainly by hypermethylation at specific loci. This is in accordance 
with an unbiased whole-genome methylome analysis that identified regions of aberrant 
methylation which also persists in differentiated cell types derived from iPSCs [18]. It was 
suggested that these epigenetic variations could either be a function of the reprogramming 
process itself [19] or they could depend on the reprogramming method used to generate these 
lines [20]. Aberrant CpG methylation demonstrated to be heavily influenced by clone-specific 
effects and seems to be correlated with MYC binding motifs [21], therefore it may be desirable 
to omit C-MYC in the reprogramming cocktail, which has been shown in mice to reduce 
tumorigenicity [22,23]. Furthermore, non-CG methylation can also serve as marker for 
predicting the potential of hPSCs to differentiate into definitive endoderm, thus linking 
variability in DNA methylation with differentiation phenotypes [24]. 
Several studies have instead attributed differences between hiPSCs lines to persistent 
remnants of epigenetic or transcriptional profiles of the donor cell type [25–28]. This retention 
of some of the characteristics of the somatic cell type of origin was termed epigenetic memory 
and was speculated to be at least in part responsible for the variability in differentiation 
capacity of different hiPSC lines [29–31]. However, the impact of epigenetic memory seems 
to vary between laboratories, somatic cell types and methods of reprogramming. Indeed, 
several reports could not detect any major influences of donor cell type on the capacity of 
differentiation while showing that hiPSCs from different donors are more divergent than 
hiPSCs originating from different somatic cell types of the same donor [32–34]. Finally, 
epigenetic memory appears to decrease after prolonged cell culture in vitro. Further 
reaffirming this notion, conclusive studies of genetically matched lines found hESC and hiPSC 
to be equivalent and imputed the few recorded differences to transcriptional noise [35,36]. 
Considered together, these results suggest that epigenetic variation and especially DNA 
methylation could have a key role in defining the differentiation capacity of hiPSCs. However, 
the source of this epigenetic variability and its functional impact on differentiation capacity 
remains controversial. 
 
Genetic factors 
Genetic variability could also have a significant influence on the capacity of hPSCs to 
self-renew and to differentiate. hiPSC lines with different genetic backgrounds could express 
divergent levels of receptors, transcription factors and growth factors which in turn could affect 
their capacity to respond to specific culture conditions. Recently even mutations in 
mitochondrial DNA have been raised as a potential additional source of variability [37]. 
However, the link between variability and genetic background has proven challenging to 
demonstrate with hESCs. Indeed, the limited number of hESC lines available precludes large 
scale studies necessary for genetic analyses. In addition, the variability induced by the process 
of derivation is difficult to evaluate since production of several hESC lines with the same 
genetic background is very challenging. Thus, the importance of genetic background has 
started to be investigated with hiPSCs. Several studies have now revealed that the 
transcriptome of hPSCs generated from different donors is more divergent than the 
transcriptome of hPSCs generated from the same donor or even from hPSCs from different 
tissue types of the same donor [35,38–40]. These reports also showed the existence of 
pluripotent specific Quantitative Trait Loci (QTL) and that allele specific variations can result 
in different levels of gene expression. Taken together, these reports suggest that genetic 
factors could influence key characteristics of hiPSCs including their capacity to differentiate 
into specific cell types. Nonetheless, functional links of differentiation capacity and molecular 
mechanisms involved remain to be fully uncovered especially the existence of specific 
“Differentiation-QTL”. The current development of large scale initiatives such as HIPSCI 
(www. hipsci.org) or the Next Gen consortium (http://www.cell.com/consortium/NextGen) 
could address this limitation (see table for a more comprehensive list of initiatives). One such 
study from the Next Gen consortium identified polycomb targets as another non-genetic 
potential cause of heterogeneity of hPSC lines [39]. Due to the potential to generate iPSCs 
from various genetic backgrounds these could serve as a good tool to validate GWAS targets 
in patient and control lines [41]. These projects are deriving a large number of hiPSC lines 
from healthy donors which could be used to perform detailed genetic analyses to link genomic 
regions with capacity of differentiation.  Such mechanisms have recently been uncovered in 
drosophila where thousands of developmental specific QTL have been identified in enhancers 
controlling expression of regulators directing embryonic development [42]. Pashos and 
colleagues have studied QTLs and allele specific expression in iPSCs and hepatocyte like 
cells and suggested that hiPSCs are a good model to discover and study genes and functional 
variants leading to complex human traits  [43]. The identification of human “differentiation-
QTL” and associated mechanisms could have a major impact on our understanding of 
development and disease progression. Indeed, such mechanisms are likely to control the 
activity of key signalling pathways and/or epigenetic networks involved in organogenesis and 
tissue repair. 
 
X-inactivation and imprinting 
Another factor displaying variability in different hPSC lines is the inactivation of the X 
chromosome. While the usual state of female somatic cells (one X chromosome active and 
one inactive, XaXi) is largely maintained during reprogramming, XaXa cells have been 
reported [44]. Furthermore, the inactivation of one X chromosome is frequently eroded with 
prolonged time in culture [45]. Indeed, a study from the Progenitor Cell Biology Consortium 
found that one of the major epigenetic differences between 58 different hiPSC lines were 
differential methylation patterns related to the X-chromosome [46]. The breakdown of X 
inactivation has been associated with increased expression of oncogenes and reduced 
developmental potential both of which could affect cell fate decisions in hPSCs  [45,47]. DNA 
methylation is also heavily influencing the allele-specific expression of imprinted genes. 
Several studies have reported changes in imprinting in mouse and human iPSC lines as a 
result of either prolonged culture or the reprogramming process [48–50] while others have 
found imprinting to be relatively stable [51]. Changes in the imprinted Dlk1-Dio3 cluster in 
mouse iPSCs have been correlated with their level of pluripotency and the ability to contribute 
to all cell types [52] thereby implying major differences in developmental potential. Finally, 
global loss of imprinting seems to heavily increase oncogenic potential [53]. Therefore, proper 
imprinting is essential to avoid functional impairment of PSCs and their derivatives. Most of 
the aspects mentioned above can be influenced by in vitro culture of hPSCs. While aberrant 
hypermethylation patterns and CNVs seem to decrease over time in iPSCs [54–56], erosion 
of X inactivation is more likely to occur [45]. Importantly, genetic and epigenetic alterations 
have been reported in hPSCs by many studies and can heavily influence their functional 
properties and oncogenic potential [57]. Culture conditions can affect the epigenetic status of 
hPSCs and constitute a major factor of inter-laboratory variability. Potentially, automated 
derivation and culture of iPSCs together with standardised culture conditions could decrease 
this source of variability [58]. It has further been suggested that reverting hPSCs to an earlier 
developmental state (ground state) could erase epigenetic signatures [59], however it has not 
been proven experimentally whether this will decrease variability of PSCs. Besides, as 
mentioned above there can be grave consequences of deleting crucial epigenetic marks such 
as imprinting. Thus, the details of an ideal hPSC culture minimising variability remain to be 
determined. 
 
Conclusions 
Variability between hPSC lines represents a major challenge for clinical applications 
since it could impair the development of personalised medicine. However, such variability 
especially when linked to genetic background could be used advantageously to investigate 
complex genetic mechanisms involved in disease using hPSC models. Nonetheless, variation 
induced by abnormal epigenetic profiles needs to be better understood and controlled. 
Improving methods of reprograming might decrease the background noise induced by such 
epigenetic mechanisms independent of the genetic background. Precise delivery of 
reprogramming factors in the right stoichiometry [60] or the inclusion of potential human 
specific factors may improve the efficiency and reproducibility of iPSC generation. Indeed, a 
broad number of studies have identified factors able to improve reprogramming efficiency of 
mouse cells (i.e. increasing the number of reprogrammed cells) however such factors are 
rarely as efficient with human cells. In addition, the qualitative effect of these factors is difficult 
to evaluate with human cells due the absence of precise test such as tetraploid 
complementation. Thus, the discovery of human specific pluripotency factors combined with 
tailored reprogramming protocols (factors, stoichiometry and timing) could help to derive high 
quality hiPSC lines. Crucially, not only the number of reprogrammed cells, but also their quality 
in terms of absence of undesirable genetic or epigenetic variations is paramount and could 
also be influenced by the precise reprogramming avenue. To ensure the best quality of 
pluripotent stem cells, especially for clinical applications, regular and detailed testing is 
essential to avoid the occurrence of oncogenic mutations or other unwanted alterations 
[61,62]. 
Another alternative to bypass the variability between hPSCs consist in purifying 
proliferative progenitors during the process of differentiation. Such approach has been 
successfully applied to isolate progenitors from the 3 germ layers endoderm [63,64] or foregut 
endoderm [65], neural stem cells [66] and mesoderm [67]. Whether this approach could be 
useful to decrease variability between different lines however remains to be shown. Indeed, 
variability in the capacity of differentiation is likely to occur at different stages of differentiation 
and thus could require purification of several intermediates. 
Ultimately, the best approach to bypass variability in differentiation and to develop 
universal protocols of differentiation is to acquire a better understanding of the molecular 
mechanisms directing hPSCs cell fate decisions and especially how the genetic and 
epigenetic background can influence these mechanisms. Thus, detailed studies are needed 
to discover the interplays by which signalling pathways directing differentiation in hPSCs 
orchestrate transcriptional networks and epigenetic states and how in turn genomic variability 
can influence the activity of key regulators. This knowledge will allow us to systematically tailor 
protocols of differentiation to specific genetic backgrounds. Ultimately, some of these 
mechanisms could also apply to adult somatic stem cells and thus deliver new insights into 
the mechanisms controlling the individual capacity for tissue repair and organ homeostasis. 
 
Figure 1: Sources of Variability 
 
Figure 2: Signalling pathways in PSC differentiation 
 
Table: Initiatives generating large numbers of iPSCs 
 
Name of 
the 
project 
Web site 
hiPSC 
lines 
(Current/ 
Objective) 
Distributor 
HISPCI 
http://www.hipsci.org/ 
500 / 800 
ECACC 
(www.pheculturecollections.org.uk/pr
oducts/celllines/ipsc/) 
NYSCF http://nyscf.org/ 21 / ? NYSCF 
WiCELL www.wicell.org 1200 WiCell 
CIRM 
www.cirm.ca.gov/rese
archers/ipsc-
repository 
1200 Coriell   (https://catalog.coriell.org/1/CIRM) 
EBISCs https://www.ebisc.org/ 367/10000 EBISCs 
NextGen 
http://www.cell.com/c
ell-stem-
cell/fulltext/S1934-
5909(17)30092-9 
? / 2000 WiCell 
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